Author Archives for Adeline Chauvigné

VitamFero files 3 new patent applications

Moving forward with the development of its vaccine platform, and following the results achieved with its avian influenza vaccine candidate... View Article

Rédigé par Adeline Chauvigné, le 2017-09-28

VitamFero files 3 new patent applications

Moving forward with the development of its vaccine platform, and following the results achieved with its avian influenza vaccine candidate... View Article

Biomedical Tissues raises €500K for the marketing and commercialisation of its landmark product – Tisseos®

Biomedical Tissues, Atlanpole Biotherapies member and a medtech company, completed a €0.5 million capital increase over the summer. The funds... View Article

Rédigé par Adeline Chauvigné, le 2017-10-09

Biomedical Tissues raises €500K for the marketing and commercialisation of its landmark product – Tisseos®

Biomedical Tissues, Atlanpole Biotherapies member and a medtech company, completed a €0.5 million capital increase over the summer. The funds... View Article

In-Cell-Art : Pass trough new steps for their Nanotaxi®

In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article

Rédigé par Adeline Chauvigné, le 2017-09-26

In-Cell-Art : Pass trough new steps for their Nanotaxi®

In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® designed to unlock the promise of nucleic acids to... View Article

Association of OSE Immunotherapeutics with GERCOR

OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer.... View Article

ArronaxPlus [video]

ArronaxPlus presentation in video !

Rédigé par Adeline Chauvigné, le 2017-07-21

ArronaxPlus [video]

ArronaxPlus presentation in video !

In-Cell-Art Announces Extension of a second Research Service Agreement with a Global Independent Vaccine Company

In-Cell-Art (ICA), a biotechnology company specializing in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat... View Article

InFlectis BioScience strengthens its intellectual property position in Europe and in the USA

InFlectis BioScience strengthens its intellectual property position in Europe and in the USA InFlectis BioScience SAS, a biopharmaceutical company specializing... View Article

Rédigé par Adeline Chauvigné, le 2017-07-06

InFlectis BioScience strengthens its intellectual property position in Europe and in the USA

InFlectis BioScience strengthens its intellectual property position in Europe and in the USA InFlectis BioScience SAS, a biopharmaceutical company specializing... View Article

OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual

OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial... View Article

OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance

OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127... View Article

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York Focused on Company’s Cytotoxic... View Article